Mode
Text Size
Log in / Sign up
N/A N=61 Randomized Treatment

Periimplant Mucosa Dynamics Around Divergent and Concave Atlantis Abutment Transition Profiles

Dental Implant, Single-Tooth · Esthetics, Dental

Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Jun 2022
Primary outcome: Primary: Peri-Implant Mucosal Zenith Distance (in Millimeters) at the Concave/Divergent Abutment Sites — 9.860; 9.770; 9.684; 9.618 millimeters

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Concave Transition Profile (Device); Divergent Transition Profile (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Christopher Barwacz
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Peri-Implant Mucosal Zenith Distance (in Millimeters) at the Concave/Divergent Abutment Sites
9.860; 9.770; 9.684; 9.618; 9.674; 9.610
SECONDARY
Submarginal Buccal-lingual Thickness (Millimeters) in the Peri-implant Transition Zone Relative to a Fixed Reference Point After Prosthesis Delivery
2.722; 2.814; 2.667; 2.597; 2.840; 2.468
SECONDARY
Keratinized Mucosa Width (Millimeters) at the Midfacial Aspect of the Implant Site.
2.704; 3.307; 3.407; 3.936; 3.620; 4.177

Summary

The purpose of this study is to compare the effect of two different implant abutment designs on gum tissue volume changes over time after implant placement.

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or greater
  • Subjects requiring replacement of a single-rooted tooth in the maxillary arch from first premolar to first premolar with an implant-supported restoration
  • Teeth adjacent (mesial and distal) to study site must consist of two stable, natural teeth without signs of periodontal bone loss (<2.0mm) and/or significant soft tissue loss
  • An opposing dentition with teeth, implants, or fixed prosthesis
  • Subjects must be willing to follow instructions related to the study procedures
  • Subjects must have read, understood, and signed the informed consent document

Exclusion Criteria

Exclusion Criteria

  • Insufficient interocclusal space for implant placement and/or restoration at study site
  • More than 2.0mm vertical bone loss at study site as measured from the mid-buccal crest of the bone on the adjacent teeth
  • Untreated rampant caries
  • Tobacco use free for ≤ 6 months
  • Liver or kidney disfunction/failure
  • Active severe infectious diseases that may affect normal healing and/or bone metabolism (e.g. AIDS)
  • Uncontrolled diabetes
  • Current alcohol or drug abuse
  • Need for systemic corticosteroids or any other medication that would influence post-operative healing and/or osseointegration
  • History of relevant head/neck cancer and/or radiation of the head/neck
  • Subjects who currently use bisphosphonates or have a history of bisphosphonate use
  • Subjects with metabolic bone diseases such as osteoporosis or Paget's disease of bone
  • Known pregnancy or nursing mothers
  • Unable or unwilling to return for follow-up visits for a period of 1 year
  • Unlikely to be able to comply with study procedures according to investigators judgement
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01871220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search